Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Front Immunol ; 12: 766278, 2021.
Article in English | MEDLINE | ID: mdl-35173705

ABSTRACT

CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.


Subject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , B-Lymphocytes/drug effects , COVID-19 Vaccines/administration & dosage , COVID-19/prevention & control , Immunization Schedule , Immunogenicity, Vaccine , SARS-CoV-2/immunology , Adult , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Biomarkers/blood , COVID-19/immunology , COVID-19/virology , COVID-19 Vaccines/immunology , Chile , Female , Granzymes/metabolism , Healthy Volunteers , Humans , Immunity, Cellular/drug effects , Immunity, Humoral/drug effects , Immunologic Memory/drug effects , Interferon-gamma/metabolism , Male , Middle Aged , Spike Glycoprotein, Coronavirus/immunology , Time Factors , Treatment Outcome
2.
J Immunol Res ; 2019: 9631515, 2019.
Article in English | MEDLINE | ID: mdl-31886313

ABSTRACT

Ovarian epithelial carcinoma (OEC) is the most frequent ovarian tumor, characterized by a high mortality in advanced stages where conventional therapies are not effective. Based on the role of the immune system in the progression of this disease, immunotherapy using checkpoint blockade has been considered as a therapeutic alternative. Nevertheless, its results do not match up to the positive results in entities like melanoma and other malignancies, suggesting the need to find other therapies to be used alone or in combination. Dendritic cell- (DC-) based vaccines have shown promising results in several types of cancer, such as melanoma, prostate, and lung cancers, due to the essential role played by DCs in the activation of specific T cells, thus using other ways of activating the immune response than immune checkpoint blockade. During the last decade, we have used DC-based vaccines loaded with an allogeneic heat shock-conditioned melanoma cell lysate in the treatment of advanced stage patients in a series of clinical trials. In these studies, 60% of treated patients showed immunological responses which correlated positively with improved survival. Considering the relevance of ovarian cancer and the promising results of our DC-based vaccine, we show here that heat shock-conditioned cell lysates derived from ovarian epithelial carcinoma cell lines have the potential to induce the phenotypic and functional maturation of human DC, which in turn, is able to induce an efficient CD4+ and CD8+ T cell-mediated immune responses against ovarian cancer cell lines in vitro. In summary, OEC heat shock-conditioned cell lysate-loaded DCs may be considered for future combined immunotherapy approaches against ovarian tumors.


Subject(s)
Carcinoma, Ovarian Epithelial/immunology , Dendritic Cells/immunology , Heat-Shock Response , Ovarian Neoplasms/immunology , T-Lymphocytes/immunology , Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Carcinoma, Ovarian Epithelial/metabolism , Carcinoma, Ovarian Epithelial/therapy , Cell Line, Tumor , Dendritic Cells/metabolism , Female , Heat-Shock Response/genetics , Heat-Shock Response/immunology , Humans , Immunotherapy , Interferon-gamma/metabolism , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/therapy , T-Lymphocytes/metabolism
3.
Methods Mol Biol ; 1997: 301-318, 2019.
Article in English | MEDLINE | ID: mdl-31119631

ABSTRACT

Macrophages are critical cells in the innate immune response to microorganisms sensed in the tissues. During infections, the interaction between pathogens and macrophages leads to a macrophage response that includes cytokine production, antigen processing and presentation in the context of MHC molecules, expression of T cell costimulatory molecules and recruitment of innate defense effectors, which results in clearance of infection. However, Neisseria gonorrhoeae can suppress the protective immune response at this level, avoiding its detection and elimination. Studies addressed to develop the interactions between macrophages and Neisseria gonorrhoeae allow us to find potential targets to be exploited with vaccines and therapeutic drugs. In this chapter, we describe protocols to generate human monocyte-derived macrophages and assess their response to infection with Neisseria gonorrhoeae.


Subject(s)
Gonorrhea/immunology , Intravital Microscopy/methods , Macrophages/immunology , Neisseria gonorrhoeae/immunology , Blood Buffy Coat/cytology , Flow Cytometry/methods , Gonorrhea/microbiology , Host-Pathogen Interactions/immunology , Humans , Immunity, Innate , Microscopy, Confocal , Phagocytosis/immunology
SELECTION OF CITATIONS
SEARCH DETAIL